Orthopediatrics Corp (KIDS) · Oct 27, 2026 · Earnings

OrthoPediatrics earnings beat revenue, raise guide; EPS trails

Beat — Revenue $72.7M vs ~$68.5M consensus; FY revenue guide raised to $270M-$273M

OrthoPediatrics earnings beat Q3 revenue expectations and lifted 2026 guidance, while adjusted EPS remained slightly below consensus.

OrthoPediatrics is scaling a pediatric-only orthopedic platform: trauma and deformity and scoliosis are the core growth engines, while its OPSB bracing business and multi-year product launch cycle are intended to expand the addressable market and improve capital efficiency. After Q2, management had already raised 2026 revenue guidance to $265 million-$269 million and was targeting annual free-cash-flow breakeven, so this quarter was mainly a test of whether that improvement was continuing.

Revenue clearly cleared expectations. Q3 revenue reached $72.7 million, up 19% year over year, versus published consensus of roughly $68.5 million—about a 6% top-line beat. Trauma and deformity grew 19% and scoliosis 18%, showing that the acceleration was broad rather than dependent on one product line.

MetricQ3 2026Q3 2025 / expectationRead
Revenue$72.7M$61.2M / ~$68.5M consensusBeat
GAAP net loss$(5.9)M$(11.8)MNarrower loss
GAAP diluted loss per share$(0.25)$(0.50)Improved year over year
Non-GAAP diluted loss per share$(0.23)$(0.24)Slightly worse than ~$0.21 consensus
Gross margin74%74%Flat
Adjusted EBITDA$6.9M$6.2MImproved
Free cash flow$1.6M$(3.4)MTurned positive
FY2026 revenue guidance$270M-$273MPrior $265M-$269MRaised

The earnings quality is mixed, not a clean double beat. The adjusted diluted loss per share of $0.23 was modestly worse than the roughly $0.21 consensus loss, even as adjusted EBITDA rose to $6.9 million from $6.2 million. Operating leverage is improving because operating expenses grew only 6% against 19% revenue growth, but the company remains GAAP-loss making and interest expense increased to $2.6 million from $1.8 million. The unchanged 74% gross margin also says the improvement is coming from scale and expense discipline, not better product economics. 〔0〕

Cash-flow progress is the most important business change. OrthoPediatrics generated $1.6 million of quarterly free cash flow after using $3.4 million a year earlier, supporting management’s annual breakeven target. That is a meaningful step for a company still investing in inventory, clinics, acquisitions and product launches, though nine-month free cash flow remained negative at $6.6 million.

The raised outlook strengthens the growth story, but does not eliminate execution risk. Full-year revenue guidance moved to $270 million-$273 million from $265 million-$269 million, while adjusted EBITDA at approximately $25 million, annual set deployment near $10 million and 2026 free-cash-flow breakeven were reiterated. The raise is directionally better than the prior expectation, but the company still had only $44.9 million in cash, short-term investments and restricted cash at quarter-end versus $62.9 million at year-end, reflecting the funding burden of expansion.

Bottom line: This advances the business story: growth is running ahead of expectations, the full-year outlook moved higher, and cash flow has begun to turn. But the slight adjusted-EPS miss and still-negative year-to-date free cash flow make it a mixed earnings report rather than an unqualified beat.

What to watch next

Q4 report and full-year 2026 cash-flow outcome

Original filing on SEC EDGAR

More Orthopediatrics Corp news

OrthoPediatrics earnings beat revenue, raise guide; EPS trails | KIDS Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.